Dupilumab for treating severe asthma with type 2 inflammation – guidance (TA751)

NICE recommend dupilumab as add-on therapy for severe asthma with type 2 inflammation that is inadequately controlled in people 12 years & over, despite maintenance therapy high-dose inhaled corticosteroids and another maintenance treatment. Several other restrictions apply.

SPS commentary:

The following restrictions apply:

  • The dosage to be used is 400 mg initially and then 200 mg subcutaneously every other week
  • The person has agreed to and follows an optimised standard treatment plan
  • The person has a blood eosinophil count of 150 cells per microlitre or more and fractional exhaled nitric oxide of 25 parts per billion or more, and has had at least 4 or more exacerbations in the previous 12 months
  • The person is not eligible for mepolizumab, reslizumab or benralizumab, or has asthma that has not responded adequately to these biological therapies
  • Dupilumab is stopped if the rate of severe asthma exacerbations has not been reduced by at least a 50% after 12 months.

National Institute for Health and Care Excellence